Acura Pharmaceuticals Profile

0.40
USD 0.0085  2.08%
87%
0%

Exercise or conversion by Reddick Andrew D of 112500 shares of Acura Pharmaceuticals subject to Rule 16b-3

Acura Pharmaceuticals insider trading alert for exercise of common stock by Reddick Andrew D, President and CEO, on May 31, 2018. This event was filed by Acura Pharmaceuticals Inc with SEC on 2011-04-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Acura Pharmaceuticals Summary

Acura Pharmaceuticals (ACUR) is traded on OTC Market in USA. It is located in ILLINOIS, U.S.A and employs 14 people. Acura Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Nano-Cap' category with current market capitalization of 8.41 M. Acura Pharmaceuticals conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 21.03 M outstanding shares of which 89.85 K shares are presently shorted by private and institutional investors with about 0.73 trading days to cover. ACURA PHARMACEUTI currently holds about 2.22 M in cash with (4.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.11.
Check Acura Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 0.4HorizonTargetOdds Above 0.4
?%30 days 0.40 ?%
Based on normal probability distribution, the odds of Acura Pharmaceuticals to move above current price in 30 days from now is about 0.0% (This Acura Pharmaceuticals probability density function shows the probability of Acura Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Selected Acura Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Acura Pharmaceuticals Against Markets

Current Ratings

Acura Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
94 
Equity ratings for Acura Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. The company was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 14 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameAcura Pharmaceuticals
CEO and President and DirectorRobert JonesView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationILLINOIS, U.S.A
Business Address616 N. North Court
ExchangeOTC Market
CIK Number00786947.0
CUSIP00509L703
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.acurapharm.com
Contact Number847 705 7709
CurrencyUSD - US Dollar

Recommendations

Acura Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
6.0Strong Buy1Odds
Acura Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Acura Pharmaceuticals Analyst Advice  

Directors

Acura Pharmaceuticals Corporate Directors
George Ross Independent Director
Bruce Wesson Independent Director
Immanuel Thangaraj Independent Director
Check also Trending Equities. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.